Accord Healthcare is seeking a Key Account Manager for the Italian market, focused on specialty brands and chronic therapies. This field-based role engages physicians, HCPs and stakeholders to drive product adoption and education with full autonomy. You
Job Title: Key Account Manager Specialty Brands Key Account Manager Role: Full-time, permanent Location: Field Emila Romagna - Triveneto Salary: Competitive + bonus + car + benefits Reporting to the Area Manager, the Key Account Manager
Descrizione dell’offerta di lavoro Job ID: 31151412Company: Abbott LaboratoriesLocation: Philippines Taguig City : Venice Corporate CenterJob Type: Full timeCategory: MarketingIndustry: HealthcarePosted Date: 2026-09-03About AbbottAbbott is a global healthcare leader, creating breakthrough science to improve people’s health.
POSITION SUMMARY: The Clinical Specialist delivers professional procedural education programs to surgeons, OR staff, and sales representatives to achieve exceptional clinical outcomes for patients. As an integral member of the Clinical and Medical Affairs (CMA) team,
Key Account Manager, Lombardia Ovest page is loaded# Key Account Manager, Lombardia Ovestlocations: Italy - Remotetime type: Full timeposted on: Posted Todayjob requisition id: 31162066# JOB DESCRIPTION: Position Overview Exact Sciences provides diagnostic gene assay testing
Territory will include multiple countries in the EU. Serving as a value-added resource and extension of the Company the Clinical Trial Liaison (CTL) will support the companys Ophthalmology & Neurology pipeline. The CTL supports the execution
Company Overview Rhythm is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. We develop medicines for previously untreatable or undertreated diseases and provide meaningful
An exciting oncology launch opportunity! Senior Medical Science Liaison Manager (F/M/X) Italy Our client is a pioneering oncology company developing innovative targeted therapies for patients with RAS-driven cancers, which account for approximately 30% of all cancer